Anti-ROR2 Antibody Engineering for Tumor Selectivity and Half-Life
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current monoclonal antibodies against ROR2 are not suitable for cancer therapy, as they have limitations in binding affinity, half-life, and side effects.
Innovation Solution
Development of anti-ROR2 antibodies or antibody fragments with higher binding affinity to ROR2 in tumors compared to normal tissues, combined with improved half-life and reduced side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current monoclonal antibodies against ROR2 are used, then they can bind to ROR2, but they have insufficient binding affinity, short half-life, and high side effects
Solution Approach 1:
The patent applies parameter changes by modifying the antibody structure through humanization and affinity maturation processes. The CDR regions are optimized to increase binding affinity to ROR2 while the constant regions are humanized to reduce immunogenicity and side effects. This resolves the contradiction by changing the molecular parameters of the antibody to simultaneously improve reliability and reduce harmful effects.
Solution Approach 2:
The patent creates composite antibody structures by combining CDR regions from non-human antibodies with human framework regions and constant regions. This composite approach allows the antibody to maintain high binding affinity to ROR2 while exhibiting reduced side effects due to human compatibility, thus resolving the technical contradiction between effectiveness and safety.
2Duration of action of moving object
If current monoclonal antibodies against ROR2 are used, then they can be administered for therapy, but they have short half-life requiring frequent dosing
Solution Approach 1:
The patent changes the pharmacokinetic parameters of the antibody through humanization of the constant regions and optimization of Fc domain properties. These parameter changes extend the half-life of the antibody in circulation, reducing the frequency of dosing required while maintaining therapeutic efficacy against ROR2-expressing cancers.
3Reliability
If anti-ROR2 antibodies with high binding affinity are developed, then therapeutic efficacy is improved, but complexity of antibody engineering increases
Solution Approach 1:
The patent applies segmentation by dividing the antibody into functional modules: CDR regions for antigen binding, framework regions for structural support, and constant regions for effector functions. This modular approach allows systematic optimization of each region to achieve high therapeutic efficacy while managing engineering complexity through standardized construction protocols.
Solution Approach 2:
The patent creates universal antibody constructs that can be adapted to target different epitopes on ROR2 using the same framework and constant regions. This multi-functional platform approach reduces overall engineering complexity by reusing validated components while maintaining high therapeutic efficacy across different antibody variants.
Data Source
AI summary
A polypeptide having a heavy chain variable region and/or light chain variable region that specifically binds to ROR2 protein as well as antibodies and antibody fragments containing the heavy chain variable region and/or the light chain variable region that bind to ROR2 protein. Pharmaceutical compositions and kits comprising the polypeptide or antibodies and antibody fragments containing the polypeptide are also provided.